Fintch (@fintchone) header
Fintch (@fintchone) profile picture

Pre-IPO and IPO opportunities. Built on real deals since 2024.

Joined September 2024
Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)Photo by Fintch (@fintchone)
Anthropic IPO. From 100 USDT. $70 – 78 indicative price per share. Now available through Fintch's new on-chain app ⬇️
24
3
35
5,329
Thanks for sharing, @stacy_muur. Just a quick clarification: we've already passed $1M in subscriptions for the Anthropic IPO deal.
In case you wanna jump in Anthrophic IPO there's a retail opportunity on @fintchone Min $100, 5% entry fee + 20% success fee + 93-day post-IPO lock-up IPO estimate is ~$1.3–1.4T and it's already close to $500K subscribed on Fintch NFA, DYOR – highlighting since I see many people want in but don't know how lol PS: Subscription closes tmr pro.fintch.one/markets/anthr…
25
Anthropic is going public. Here’s what’s driving Claude’s growth and how investors can use USDT to seek exposure at the IPO offer price.
1
80
Thanks to @castle_labs for including Fintch in this week’s Castle Chronicle.
Replying to @castle_labs
Anthropic's IPO is at about a $1.4 trillion valuation. Being one of the largest IPOs, the demand is huge, and getting an allocation can be difficult. In today's newsletter, we explored one way to gain exposure: through @fintchone.
1
3
31
The Anthropic’s indicative IPO range is still $70–78. Pre-IPO perps have been trading well above it. @fintchone is currently taking on-chain subscriptions at that range, starting at 100 USDT. The part I’d watch closely is the fill, allocation isn’t guaranteed.
🤝 Paid partnership
Anthropic IPO. From 100 USDT. $70 – 78 indicative price per share. Now available through Fintch's new on-chain app ⬇️
6
6
440
23,140
Anthropic deal terms: • Subscription closes November 18 • Allocation is not guaranteed • Unallocated funds are refunded • 5% entry fee / 20% success fee Explore the deal: pro.fintch.one/markets/anthr…
3
4
151
🧠 Anthropic IPO: the countdown begins $70–78 per share. An expected November 19 debut. A valuation around $1 trillion. We previously shared access to Anthropic through Fintch. Now the company behind Claude has launched its IPO roadshow and announced its indicative price range — bringing its Nasdaq debut another step closer. Trading is expected to begin on November 19, subject to change. At roughly $1 trillion on a basic-share basis, the question is not just how fast AI adoption can grow — but how much of that growth is already priced in. Participation through Fintch: • Minimum investment: 100 USDT • Lock-up period: 93 days 📅 Deadline: November 18, 2026. 📲 Explore Anthropic in Market and submit your application: apps.apple.com/app/fintch/id…
16
19
220
🦷 New IPO: vVARDIS Holding A new IPO opportunity is coming to the Fintch app. Treat early tooth decay without the drill. Swiss dental technology company vVARDIS is building its business around that approach. Its Curodont platform uses self-assembling peptides to support enamel remineralization. Treatment takes approximately five minutes, without drilling or injections. It has already been used on more than 3.5 million teeth and supplied to over 20,000 US dental practices. Bet on: growing adoption of minimally invasive dentistry + rapid commercial growth. First-half 2026 revenue rose 214.2% to $28.6M. Henry Schein provides exclusive US distribution, while Apollo backs the company. Adoption is growing, but the price demands execution. The proposed $4.1B valuation represents approximately 82x trailing revenue. vVARDIS remains loss-making and depends heavily on one flagship product and its US distribution partner. 📊 Key terms & financials - Indicative price: $21.00-24.00 per share - IPO valuation: approximately $4.1B - Target IPO proceeds: $214.3M - Revenue: $49.7M for the 12 months ended June 30, 2026 - Net loss: $52.2M over the same period - H1 2026 revenue: $28.6M (+214.2% YoY) - Ticker: VVVV - Expected listing: November 13, 2026 | NYSE - Lock-up period: 93 days - Minimum investment: 100 USDT Expected upside: 20% (not guaranteed) 📅 Deadline:: November 12, 2026. 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
4
9
164
🧬 New IPO: Windward Bio Group AG A new IPO opportunity is coming to the Fintch app. Two injections a year instead of twelve. That is the ambition behind Windward Bio’s lead drug candidate, WIN378, for asthma and COPD. The Swiss biotech develops long-acting antibodies targeting inflammation. WIN378 targets TSLP, the same pathway addressed by the approved treatment Tezspire, but aims to extend dosing from monthly to once every six months. Bet on: a validated treatment target + a potential advantage in convenience. WIN378 is in Phase 3 development for asthma and Phase 2 for COPD. Investors include OrbiMed, Novo Holdings, Sanofi Ventures, and RA Capital. The challenge is proving that fewer injections can deliver sustained efficacy and safety. Windward has no revenue, competing treatments are advancing, and pivotal asthma results are expected in the first half of 2029. Additional financing may be needed. 📊 Key terms & financials - Indicative price: $16.00-18.00 per share - IPO valuation: approximately $986.7M at the midpoint - Target IPO proceeds: $174.9M - Revenue: $0 - Net loss: $68.2M for the 12 months ended June 30, 2026 - Ticker: WWB - Expected listing: November 13, 2026 | Nasdaq - Lock-up period: 93 days - Minimum investment: 100 USDT Expected upside: 20% (not guaranteed) 📅 Expected pricing: November 12, 2026. 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
2
90
🖥 New Pre-IPO: xFusion A new pre-IPO opportunity is now available in the Fintch app. xFusion develops AI servers, general-purpose computing systems, liquid-cooled data center infrastructure, and enterprise software. Spun out of Huawei’s server business in 2021, it operates across more than 130 countries and regions. The company ranked second in China’s server market in 2025. Bet on: expanding AI infrastructure demand + an established server business. AI servers generated more than half of core business revenue in 2025. First-half 2026 net income reached $297M, exceeding the full-year 2025 total. The entry valuation represents approximately 1.26x 2025 revenue but 71x earnings. A low revenue multiple does not automatically mean a cheap business: 2025 net margin was approximately 1.8%. The key question is whether stronger recent profitability can persist in a competitive hardware market. 📊 Key terms & financials - Indicative purchase price: $10.50 per share - Pre-IPO valuation: approximately $10.4B - 2025 revenue: approximately $8.2B (+31.6% YoY) - 2025 net income: $145M - H1 2026 revenue: approximately $5.3B - H1 2026 net income: $297M - Recent equity financing: at least $550M - Planned listing venue: ChiNext | Shenzhen - Listing application review: November 12, 2026 - IPO date: not announced - Minimum investment: 100 USDT Expected upside: 70% (not guaranteed) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
2
56
💳 New IPO: OPay Limited (#OPAY) A new IPO is now available in the Fintch app. OPay Limited is a Singapore holding company behind OPay, a digital banking and fintech platform spun out of browser maker Opera in 2017 - founder Zhou Yahui also built Kunlun Tech and backs Opera. OPay is Nigeria's #1 digital bank and payments platform, and per Frost & Sullivan, the #1 fintech app in Africa and the Middle East by monthly active user share (9.9% as of Jun 30, 2026) - in Nigeria it ranks #2 among all apps by daily active users, competing with social media and messengers for attention, not just other fintechs. The platform serves consumers (wallet, transfers, bill pay, OWealth savings, microloans, airtime top-up) and merchants (POS acquiring, agent network). Nigeria is the core market; Indonesia (lending), Egypt and Pakistan (merchant acquiring, wallets) are early-stage expansion. SoftBank Vision Fund 2 led a $400M round at a $2B valuation in 2021. Bet on: a financial super-app for a largely unbanked population - instant P2P transfers, bill pay, airtime, QR payments, monetized through transaction fees, merchant acquiring, and interest/spread on savings and microloans + real network effects at scale: 50M MAU and $558B in GTV, where growth on either side of the marketplace reinforces the other + operating leverage already showing up - a 2024 loss flipped to a 2025 profit, then $90.9M net income in H1 2026 alone on the same cost base + anchor orders covering ~84.4% of the IPO book, including a $200M private placement from Standard Bank, Africa's largest bank, now also a strategic partner. 📊 Key terms - Price range: $19-21 per ADS - ADS offered: 16,000,000 - Gross proceeds: ~$320M at midpoint - Market cap: ~$4.2B at midpoint - more than double the $2B 2021 funding valuation - Exchange: NYSE | Ticker: OPAY - Pricing: October 29, 2026 | Trading: October 30, 2026 - Lock-up: 93 days - Use of proceeds: technology, distribution, new products, new market entry, potential M&A 💰 Financials - Revenue: $205.7M (2024) → $536.3M (2025, +161%) | LTM to Jun 30, 2026: $806M | H1 2026: $467.1M vs. ~$197M a year earlier (+137%) - Net income: -$50.8M (2024) → +$72.5M (2025) → +$90.9M in H1 2026 alone - Scale (LTM to Jun/Jul 2026): ~50.1M MAU, 26.8M DAU, 90.1B transactions, $558B GTV - Revenue concentration: 89.5% from Nigeria in H1 2026 - Valuation at $4.2B: ~5.2x TTM revenue ($806M); ~20-23x forward P/E on an annualized ~$180M net income - moderate for a profitable, 137%-growth fintech, though it doesn't price in Nigeria currency/country risk 🎯 Thesis OPay is the rare profile in this IPO wave: not biotech, not US tech, but a profitable, hypergrowth fintech dominating a developing-market super-app category - the same playbook that built Nubank in Brazil and Mercado Pago in Latin America. The anchor-heavy book (~84% covered, with Standard Bank as both strategic partner and anchor) makes demand close to pre-committed. Key risk: 89.5% of revenue sits in Nigeria, exposing the stock to naira volatility, Central Bank of Nigeria regulatory risk, and competition from Moniepoint and PalmPay - plus governance questions tied to the Opera/Kunlun ownership chain that EM investors typically discount for. 🏛️ Joint bookrunners: Citigroup, Deutsche Bank Securities, Standard Bank, CICC. 📅 Deadline: October 29, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
2
190
🧬 New IPO: Lycia Therapeutics (#LYCA) A new IPO is now available in the Fintch app. Lycia Therapeutics is a South San Francisco clinical-stage biotech built around LYTAC, a platform co-founded by Nobel laureate Carolyn Bertozzi (2022 Chemistry Prize, click chemistry) that degrades extracellular and membrane proteins - not just the intracellular targets classic PROTAC degraders hit. CEO Aetna Wun Trombley. Instead of merely blocking a pathogenic protein like an antibody does, LYTAC routes it to the lysosome via uptake receptors for destruction; the newer cataLYTAC variant works catalytically, so one drug molecule can degrade many target molecules. Roughly 40% of human proteins are extracellular or membrane-bound - a space PROTAC companies can't reach. Bet on: lead asset LCA-0061, a cataLYTAC IgE degrader in Phase 1 for elevated-IgE conditions including food allergy - IgE is a clinically validated target (Xolair, $4B+ in sales) and catalytic degradation could clear IgE more deeply and durably than antibody blockade + LCA-0321, a LYTAC degrader for Graves' disease that destroys the pathogenic TRAb autoantibodies directly - a mechanism no other therapeutic approach offers today + Eli Lilly as a strategic investor, backing both the platform and the IPO book + a crossover syndicate (OrbiMed, RTW, Venrock Healthcare, Janus Henderson, Balyasny, Adage, Franklin Templeton, Invus, HBM) that's unusually strong for a Phase 1 biotech. 📊 Key terms - Price range: $16-18 per share (midpoint $17) - Shares: 14,700,000 + underwriters' option - Gross proceeds: ~$249.9M at midpoint - Market cap: ~$885.6M at pricing - Exchange: Nasdaq Global Market | Ticker: LYCA - Terms set: October 20, 2026 | Pricing: October 22, 2026 | Trading: October 23, 2026 - Lock-up: 93 days - Use of proceeds: LCA-0061 and LCA-0321 through Phase 1 proof-of-concept, LCA-0062 toward clinical readiness, LYTAC/cataLYTAC platform development, working capital 💰 Financials - Product revenue: $0 - clinical-stage - Collaboration revenue: $4.4M (LTM to Jun 30, 2026) - Net loss: $30.03M (LTM to Jun 30, 2026) - a relatively disciplined burn heading into an IPO - Private capital raised: Series C $106.6M (May 2024), Series D $75M (Jun 2026, oversubscribed), plus earlier rounds - Investors: Eli Lilly (strategic), OrbiMed, RTW, Venrock Healthcare, Janus Henderson, Balyasny, Adage, Franklin Templeton, Invus, HBM - Runway: pre-IPO cash + ~$250M IPO - funds several years, through Phase 1 proof-of-concept data for both lead programs - Valuation: ~$885.6M at pricing (up to ~$938M) - a premium for Phase 1, priced on the Nobel-backed platform, the investor syndicate, and Lilly's strategic backing 🎯 Thesis Lycia is a platform bet on a genuinely novel modality: no other company directly degrades extracellular targets like pathogenic autoantibodies (TRAb in Graves') or IgE at this stage. The $250M raise and crossover syndicate signal real institutional conviction for a Phase 1 name, and Eli Lilly's strategic stake adds validation plus a plausible future partnership path. Key risk: LYTAC is clinically unproven - the science is Nobel-caliber, but no degrader of this class has yet shown it works in humans at scale, and IgE-targeted competition from an already-approved $4B+ drug (Xolair) sets a high bar. 🏛️ Lead bookrunner: Jefferies. Joint bookrunners: TD Securities, Evercore ISI, Guggenheim Securities, LifeSci Capital. 📅 Deadline: October 22, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
2
245
🤖 New IPO: Iambic Therapeutics (#IAM) A new IPO is now available in the Fintch app. Iambic Therapeutics is a San Diego clinical-stage biotech-meets-AI company, founded in 2019 as Entos, developing oncology drugs on a proprietary AI platform that pairs machine learning with automated chemistry and biology experiments. CEO Dr. Thomas Miller. The company's headline achievement: Iambic took its first drug candidate to clinical trials in roughly 2 years - more than 3 years faster than the industry average - running a closed loop where AI generates hypotheses, automated experiments produce data, and that data retrains the models. Iambic bets on owning its own drugs outright rather than running a pure fee-for-platform model; partnered work is treated as supplementary, not core. Bet on: Nvidia as a strategic technology partner providing compute and co-development input - real third-party validation of the AI stack + a proprietary closed-loop platform generating its own experimental data to retrain its models, not licensed or public datasets + three wholly-owned oncology programs, led by IAM1363 - an oral small-molecule HER2 inhibitor differentiated from the market's dominant HER2 antibody-drug conjugates (Enhertu) by being oral and potentially crossing the blood-brain barrier + anchor investors ARK and Duquesne committing $60M into the book. 📊 Key terms - Price range: $15-17 per share - Shares: 9,375,000 + underwriters' option (30-day) - Gross proceeds: ~$150M at range midpoint - Market cap: up to ~$805.8M at top of range ($17) - Nvidia holds ~9.6M pre-IPO shares as strategic partner - Exchange: Nasdaq Global Select Market | Ticker: IAM - Pricing: October 14, 2026 | Trading: October 15, 2026 - Lock-up: 93 days - Use of proceeds: three early-stage oncology programs (IAM1363 Phase 1/1b; IAM217 and IAM-C1 toward IND filing), AI platform development, working capital 💰 Financials - Revenue: $0 - clinical-stage, no marketed products - Private capital raised to date: ~$461.8M across Series B $106.2M (2023), B-2 $65.3M (2024), B-3 $119.3M (2025-2026), B-4 $32.8M (2026), plus earlier rounds - Investors: Nvidia, Q Healthcare Holding (Qatar Investment Authority), Catalio Capital, Nexus Venture Partners, Coatue Management - Anchor orders: ARK and Duquesne, $60M combined - Runway: ~$461.8M raised to date + ~$150-159M IPO + $60M anchor orders - one of the best-capitalized names in this biotech IPO wave, funding several years including first clinical readouts - Valuation: up to ~$805.8M at the $17 top of range - a moderately rich "platform premium" for a Phase 1 oncology biotech; the market will be weighing that premium against Phase 1-stage risk 🎯 Thesis Iambic sits at the intersection of two categories investors watch closely: AI-driven drug discovery and Phase 1 oncology. The Nvidia partnership and self-reinforcing data loop differentiate it from "AI biotech" peers leaning on licensed datasets, and owning assets outright means it captures full upside if IAM1363 works. The risk is the comp set: Recursion, Schrödinger, Relay, and AbCellera have mostly traded down post-IPO as markets stopped paying for "AI platform" and started pricing clinical data - and two of Iambic's three programs haven't reached the clinic yet. 🏛️ Lead bookrunners: J.P. Morgan, Jefferies, BofA Securities, Citigroup. 📅 Deadline: October 14, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
1
292
💍 New IPO: Oura Health (#OURA) A new IPO is now available in the Fintch app. Oura Health is a health-tech company behind the Oura Ring - a titanium smart ring tracking sleep, readiness, activity, heart health, and other biometrics. Founded 11 years ago in Finland; redomiciled to Delaware in March 2026 to streamline the US listing. Co-CEOs Tom Hale and Shyamal Patel. Oura effectively created the smart ring category and has defended its lead since Samsung entered with the Galaxy Ring. Bet on: a hardware-plus-subscription model with conversion above 94% - almost every ring buyer signs up for Oura Membership + 5M paid subscribers, up 2x YoY + profitability that's rare for a consumer health-tech IPO: net income swung from ~$1.6M to ~$59-61M TTM while revenue grew 74% + Eli Lilly as an anchor investor ($100M) - Oura positions as the companion device for GLP-1 weight-loss therapy, tracking the metabolic and cardiovascular metrics that matter during treatment + a data moat that compounds: years of biometric data across millions of users improves the product's personalized insights as it scales. 📊 Key terms - Price range: $40-44 per share - Shares: 50,000,000 + underwriters' option up to 7,500,000 (30-day) - Gross proceeds: up to ~$2.2B at $44 - Market cap: ~$15.62B at top of range, fully diluted - Exchange: Nasdaq Global Select Market | Ticker: OURA - Pricing: September 29, 2026 | Trading: September 30, 2026 - Lock-up: 93 days - Prior valuation: ~$11B (Series E, Oct 2025, led by Fidelity, $900M+ raised) - IPO values the company ~1.4x higher 11 months later 💰 Financials - LTM revenue (Jun 2026): ~$1.4B | 9-month revenue (through Jun 30, 2026): $1.21B (+74% YoY) - LTM net income: ~$59-61M, up from ~$1.6M a year earlier - Rings shipped (9 months): 3.1M units | Paid subscribers: 5M (2x YoY), 94%+ conversion - Total funding pre-IPO: ~$1.5B across 10 rounds - Valuation at $44: ~11.2x LTM revenue, ~9.8x annualized 9-month revenue, ~260x LTM net income - the high P/E reflects growth and subscription optionality, not current earnings - Comps: Garmin (~$40B cap, ~5x revenue, ~10% growth); Whoop (private, subscription-heavy model) 🎯 Thesis Oura is pricing as a premium consumer health-tech platform, not a hardware company - ~10x revenue with 74% growth and actual profitability is a rare combination for this IPO wave. The moat is data plus habit: near-universal subscription attach and a ring people wear to bed builds a sleep/recovery dataset competitors can't easily replicate, and the GLP-1 tailwind (Lilly's backing) gives it a growing adjacent use case beyond fitness tracking. Key risk: Samsung and Apple have the resources to contest this category directly, and retail customer concentration plus reliance on third-party AI vendors are flagged in the S-1. 🏛️ Lead bookrunners: Goldman Sachs, Morgan Stanley, J.P. Morgan. Additional bookrunners: Allen & Company, Jefferies. Five-bank, Tier-1-heavy syndicate - one of the strongest seen in consumer tech this year, comparable to the Bending Spoons lineup. 📅 Deadline: September 29, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
2
288
🚀 Enflame surged on debut - this is what exclusive access looks like Enflame listed on China's STAR Market (Shanghai) on September 11. IPO price was RMB 142.18 - the stock opened at RMB 410, ran as high as RMB 475 intraday, and closed the debut session up roughly 188-206%. This is exactly the kind of setup Fintch opened access to weeks before listing: the last of China's "Four GPU Dragons" to go public, priced at ~61.8x 2025 revenue while its already-listed peers (Moore Threads, MetaX, CXMT) were trading at 160x+. The gap closed the way we expected. One thing to keep in mind if you're in this position: lock-up is 365 days from entry. This is a hold, not a flip - the value shows up on paper today, but the position stays closed until the lock-up clears. 📲 Explore what's open now in the Fintch app: apps.apple.com/app/fintch/id…
1
91
🔬 New IPO: CanSemi Technology (#301660) A new IPO is now available in the Fintch app. CanSemi Technology is a Guangzhou-based 12-inch specialty semiconductor foundry, manufacturing chips to order for other developers - analog and power ICs, image sensors, and silicon photonics solutions for AI data centers. Founded 2017, mass production since 2019. Shareholders include Guangdong provincial state funds and state investment corp SDIC. Bet on: the only mainland Chinese producer running mass production of 12-inch silicon photonics wafers, per the company - the tech behind high-speed optical links inside AI data centers + fab utilization at ~96%, the foundry sells nearly everything it produces + revenue up ~2.5x in two years (¥1.04B to ¥2.58B) + 200+ clients, ~40 publicly listed, chips already in VIVO and OPPO fingerprint scanners + China's chip self-sufficiency push as the structural tailwind: domestic production covers only ~16% of the country's analog chip demand, under 10% in automotive - foreign suppliers (Texas Instruments, Analog Devices, Infineon) still hold a large share of that market. 📊 Key terms - Entry price: $2.54 per share - Subscription opens: September 24, 2026 - Exchange: ChiNext | Ticker: 301660 - Target raise: ¥7.5B, floating ~17.8% of shares - Implied IPO market cap: ~¥42B | Our entry valuation: ~¥40B (~$6B) - at or slightly below the IPO reference level - Instrument: forward contract, via licensed Hong Kong broker - Lock-up: 12 months from IPO date 💰 Financials - Revenue: ¥1.04B → ¥2.58B over two years (~2.5x growth) - Fab utilization: ~96% - Client base: 200+ clients, ~40 publicly listed companies 🎯 Thesis CanSemi is an import-substitution bet inside China's biggest structural chip gap - analog and automotive semiconductors, where domestic supply still falls far short of demand. Recent Chinese chip listings on this wave have rallied hard post-IPO: Moore Threads +425% on debut, CXMT +466%, Enflame +292%; closest public comp by business model, Nexchip, is up more than 2x since April. Entry here is priced at or below the IPO reference level, ahead of the same catalyst. Key risk: aftermarket pops of this size aren't guaranteed to repeat, and the deal is structured as a forward contract through a Hong Kong broker, not a direct share purchase. ⚠️ Risk: Medium | Entry fee: 5% | Success fee: 20% of profit | Minimum: 100 USDT 📅 Deadline: September 24, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
3
177
⚛️ New IPO: Holtec Nuclear Corp (#HNUC) A new IPO is now available in the Fintch app. Holtec Nuclear Corporation is a Camden, New Jersey vertically integrated nuclear technology company founded in 1986 by Dr. Krishna P. Singh, still CEO and Executive Chairman with control through Class B shares carrying 10 votes each. Its HI-STORM dry storage system has been the industry standard for two decades: 217 patents, three US plants, 150+ reactors on five continents. Holtec owns the 800+ MW Palisades plant in Michigan and is working to restart it, while developing the SMR-300 small modular reactor. Bet on: three businesses under one roof - spent fuel storage (≈75% US share in dry storage, >90% in wet, held for decades because switching cask vendors mid-operation is expensive and disruptive) + decommissioning contracts funded by utility trust funds, predictable multi-year revenue + a growth arm (Palisades, SMR-300) the first two fund internally, so it doesn't raise like a pure-play SMR startup + DOE backing: a $1.52B loan guarantee, a $400M First Mover grant, plus $300M from Michigan. 📊 Key terms - Price range: $15-18 per share | Market cap at $18: ~$10.2B - Shares: 50,000,000 (Class A) + 7,500,000 over-allotment - Gross proceeds: ~$825M at the $16.50 midpoint - Exchange: Nasdaq Global Select + Nasdaq Texas | Ticker: HNUC - Pricing: September 17 | Trading: September 18, 2026 | Lock-up: 93 days - Use of proceeds: SMR-300 deployment, Palisades restart, general corporate purposes 💰 Financials - LTM revenue (Mar 31, 2026): $989M | FY2025: $576.6M, of which $529.0M from site construction - Net income: $386.6M - but a large share is investment income on decommissioning trust funds, not operating profit on products - Capex 2025: $983.6M, mostly Palisades and SMR-300 - Valuation: ~10.3x LTM revenue at $18, ~9.5x at the $16.50 midpoint (~$9.35B). Priced as an option on future Palisades cash flows and SMR-300 upside, not on current business 🎯 Thesis Holtec is the only vertically integrated player holding a dominant cash-generating storage business, its own reactor restart, and an SMR program at once. Unlike Oklo and NuScale - pure SMR names with no revenue - it has revenue and profit today. The tailwind: the US target of 400 GW of nuclear by 2050 is a 4x expansion, and nuclear is the only zero-carbon baseload for AI data centers. The question: the multiple assumes Palisades and SMR-300 both deliver, while today's profit leans on trust fund income rather than product margin. 🏛️ Bookrunners: J.P. Morgan, Guggenheim, Goldman Sachs, Citigroup, BofA, plus Morgan Stanley, Cantor, BMO, Oppenheimer. Nine banks with five Tier-1 co-leads - comparable to SK Hynix and SpaceX. 📅 Deadline: September 17, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
1
209
🏠 New IPO: Orion180 Insurance Group (#OIG) A new IPO is now available in the Fintch app. Orion180 Insurance Group Inc. is a technology-focused specialty insurance group headquartered in Melbourne, Florida, founded in 2018 by Kenneth Gregg, still CEO. It has grown organically into the second-largest E&S homeowners insurer in the US by direct written premium: 14 states, ~$503-506M of premium under management as of March 31, 2026, 580,000+ policies since inception. Products span E&S and admitted homeowners insurance, FLEX Home, and private flood insurance, sold through 12,000-14,000+ independent agents on the proprietary MY180 underwriting platform. Bet on: a hybrid model separating fee income from underwriting risk - the MGA segment (claims, technology, IoT) earns commission outside the regulated carriers, low capital intensity and high margin, while fronting carriers retain part of the risk and cede the rest to highly rated reinsurers + E&S focus giving pricing flexibility rigid admitted policies don't allow + the opening created by incumbents pulling capacity out of high-risk coastal southern US + 70%+ of new claims handled in-house, settled in 21 days on average. 📊 Key terms - Price range: $15-17 per share | Target market cap: ~$1.58B at the midpoint - Shares: 20,000,000 (Class A) + 3,000,000 over-allotment - Gross proceeds: ~$320M at the $16 midpoint - Exchange: Nasdaq Global Select Market | Ticker: OIG - Pricing: September 17 | Trading: September 18, 2026 | Lock-up: 93 days - Use of proceeds: growth capital, general corporate purposes, possible partial repayment of a new credit facility 💰 Financials - LTM revenue (Jun 30, 2026): $153.14M | LTM net income: $26.82M - H1 2026 revenue: $80.1M (+59%) | net income: $13.5M, a swing from a $3.0M loss - FY2025 revenue: $123.5M (+38.3% YoY) | net income: $16.3M - Direct written premium (LTM): $601M - Combined ratio: 124.7% in H1 2026 vs 158.4% (-33.7 pp); FY2025 107.0% vs 148.9% (-41.9 pp) - Direct loss ratio: 34-36% since inception, ~30 pp better than the industry average - Premium under management: $2M (2018) → $65M (2021) → $263M (2024) → $444M (2025) - Valuation at $17 (~$1.68B): ~11x LTM revenue, ~63x LTM net income 🎯 Thesis Orion180 is asking to be valued as a fast-growing insurtech, not a traditional insurer - P&C carriers trade at 1-2x book or 10-15x earnings, this prices at ~11x revenue and ~63x earnings. What supports it: the company is profitable, unlike Lemonade, Root, and Hippo, all trading well below their IPO valuations. E&S specialization, the tech platform, and partial risk retention separate it from pure MGA models like Bamboo, also filing. Competitors: Kingstone, HCI Group, Universal, Heritage, American Coastal. The central question: does a tech multiple hold for an E&S homeowners writer with catastrophe exposure and a combined ratio still above 100%? Climate cuts both ways - severe weather raises demand and pricing power, and raises catastrophe losses. 🏛️ Bookrunners: RBC Capital Markets, UBS, Raymond James, plus Goldman Sachs, Deutsche Bank, Citizens Capital Markets (JMP), Texas Capital. Seven banks is unusually broad for a homeowners insurer raising $320M - that lineup signals real demand. 📅 Deadline: September 17, 2026 (inclusive) 📲 Explore the deal in the Fintch app: apps.apple.com/app/fintch/id…
1
161
🔥 PRE-IPO DROP: Enflame - the last of China's "Four GPU Dragons" to hit the market Three of its peers already listed. Every single one is trading multiples above its IPO price. This is the last shot at getting in before Enflame does the same. Who they are 👇 Enflame Technology is a Chinese semiconductor company building proprietary AI accelerator chips - compute cards, modules, intelligent computing systems, clusters, and the software stack around them - for cloud and data center AI workloads. Founded 2018. Backed by Tencent, who's both a shareholder and a strategic placement participant in this raise. Why this matters: The last three chip-sector IPOs on the same exchange (STAR Market) all popped hard on day one and never looked back - Moore Threads and MetaX (Dec 2025), Biren (HK, Jan 2026), CXMT (Jul 2026) rallied +76% to +693% on debut, and none has ever traded back down to its IPO price, even after 40-50% pullbacks from peak: 🔹 MetaX: trading 6.4-7.0x its IPO price 🔹 CXMT: 6.1x 🔹 Moore Threads: 4.7x 🔹 Biren: 1.8-1.9x Enflame's entry valuation: ~61.8x 2025 revenue - versus 160x+ for its already-listed peers. Same sector, same exchange, same wave - priced at a fraction of where the market has been putting this category. 📊 Entry terms Company valuation: RMB 61.19B (~$9.12B) Entry price: $21.16 per share Instrument: forward contract The catch - read this: Lock-up: 365 days from entry. This is a position you hold through the listing and beyond, not one you flip. 💼 Entry fee: 5% | Success fee: 20% of profit Minimum investment: 100 USDT 📅 Deadline: September 10, 2026 (inclusive) 📲 Claim your spot in the Fintch app: apps.apple.com/app/fintch/id…
1
2
53